Percutaneous coronary intervention with oral sirolimus and bare metal stents has comparable safety and efficacy to treatment with drug eluting stents, but with significant cost saving: long-term follow-up results from the randomised, controlled ORAR III (Oral Rapamycin in ARgentina) study

Abstract

A strategy of OR plus BMS is cost saving compared to DES in patients undergoing PCI for de novo coronary lesions.